Franklin Resources Inc. Raises Position in IQVIA Holdings Inc. $IQV

Franklin Resources Inc. raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 20.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 505,239 shares of the medical research company’s stock after acquiring an additional 86,016 shares during the quarter. Franklin Resources Inc. owned approximately 0.30% of IQVIA worth $113,886,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in IQV. Brighton Jones LLC lifted its stake in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares during the period. Empowered Funds LLC lifted its stake in shares of IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after purchasing an additional 4,915 shares during the period. Sivia Capital Partners LLC purchased a new position in shares of IQVIA in the 2nd quarter valued at approximately $514,000. First Trust Advisors LP lifted its stake in shares of IQVIA by 14.8% in the 2nd quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after purchasing an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC lifted its stake in shares of IQVIA by 5.4% in the 2nd quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after purchasing an additional 1,155 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Truist Financial lowered their target price on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. Evercore restated an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a research note on Wednesday, April 8th. Mizuho set a $215.00 price target on IQVIA in a research note on Monday, February 23rd. Finally, Royal Bank Of Canada assumed coverage on IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $224.13.

IQVIA Stock Performance

IQVIA stock opened at $182.28 on Thursday. The company has a market capitalization of $30.42 billion, a P/E ratio of 22.59, a PEG ratio of 1.60 and a beta of 1.21. IQVIA Holdings Inc. has a twelve month low of $153.01 and a twelve month high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock’s 50 day moving average is $173.18 and its 200 day moving average is $194.08.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its board has initiated a stock repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.